Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Minerva Neurosciences stock
Learn how to easily invest in Minerva Neurosciences stock.
Minerva Neurosciences Inc is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 11 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Minerva Neurosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – NERV – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Minerva Neurosciences stock price (NASDAQ: NERV)Use our graph to track the performance of NERV stocks over time.
Minerva Neurosciences shares at a glance
|Latest market close||$0.74|
|52-week range||$0.71 - $3.69|
|50-day moving average||$0.95|
|200-day moving average||$1.81|
|Wall St. target price||$7.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.84|
Buy Minerva Neurosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Minerva Neurosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Minerva Neurosciences price performance over time
|1 week (2022-01-19)||-9.47%|
|1 month (2021-12-24)||N/A|
|3 months (2021-10-28)||-46.00%|
|6 months (2021-07-28)||-61.27%|
|1 year (2021-01-28)||-76.74%|
|2 years (2020-01-28)||-91.29%|
|3 years (2019-01-28)||6.45|
|5 years (2017-01-27)||10.75|
Is Minerva Neurosciences stock undervalued or overvalued?
Valuing Minerva Neurosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Minerva Neurosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Minerva Neurosciences's EBITDA
Minerva Neurosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.6 million.
The EBITDA is a measure of a Minerva Neurosciences's overall financial performance and is widely used to measure a its profitability.
Minerva Neurosciences financials
|Gross profit TTM||$19.1 million|
|Return on assets TTM||-24.03%|
|Return on equity TTM||-83.45%|
|Market capitalisation||$31.2 million|
TTM: trailing 12 months
Minerva Neurosciences share dividends
We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.
Minerva Neurosciences share price volatility
Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $0.71 up to $3.693. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 0.886. This would suggest that Minerva Neurosciences's shares are less volatile than average (for this exchange).
Minerva Neurosciences overview
Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc.
Minerva Neurosciences in the news
Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition
Stocks making the biggest moves midday: Netflix, Kohl's, Wynn Resorts, General Motors and more
RBC upgrades Comcast to outperform on subscriber growth
Frequently asked questionsWhat percentage of Minerva Neurosciences is owned by insiders or institutions?
Currently 3.402% of Minerva Neurosciences shares are held by insiders and 58.541% by institutions. How many people work for Minerva Neurosciences?
Latest data suggests 11 work at Minerva Neurosciences. When does the fiscal year end for Minerva Neurosciences?
Minerva Neurosciences's fiscal year ends in December. Where is Minerva Neurosciences based?
Minerva Neurosciences's address is: 1601 Trapelo Road, Waltham, MA, United States, 02451 What is Minerva Neurosciences's ISIN number?
Minerva Neurosciences's international securities identification number is: US6033801068 What is Minerva Neurosciences's CUSIP number?
Minerva Neurosciences's Committee on Uniform Securities Identification Procedures number is: 603380106
More guides on Finder
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Ask an Expert